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Abstract
Background: Periodontitis has been implicated as a risk factor for metabolic disorders associated with insulin
resistance. Recently, we have demonstrated that orally administered Porphyromonas gingivalis, a representative
periodontopathic bacterium, induces endotoxemia via reduced gut barrier function coupled with changes in gut
microbiota composition, resulting in systemic inflammation and insulin resistance. Propolis, a resinous substance
collected by honeybees from leaf buds and cracks in the bark of various plants, can positively affect metabolic
disorders in various experimental models. In this study, we thus aimed to clarify the effect of propolis on impaired
glucose and lipid metabolism induced by P. gingivalis administration.
Methods: Eight-week-old male C57BL/6 mice were orally administered P. gingivalis strain W83, propolis ethanol
extract powder with P. gingivalis, or vehicle. We then analyzed the expression profile of glucose and lipid
metabolism-related genes in the liver and adipose tissues. Serum endotoxin levels were also evaluated by a
limulus amebocyte lysate test. In addition, we performed histological analysis of the liver and quantified alveolar
bone loss by measuring the root surface area on the lower first molar.
Results: Oral administration of P. gingivalis induced downregulation of genes that improve insulin sensitivity in
adipose tissue (C1qtnf9, Irs1, and Sirt1), but upregulation of genes associated with lipid droplet formation and
gluconeogenesis (Plin2, Acox, and G6pc). However, concomitant administration of propolis abrogated these adverse
effects of P. gingivalis. Consistent with gene expression, histological analysis showed that administered propolis
suppressed hepatic steatosis induced by P. gingivalis. Furthermore, propolis inhibited the elevation of serum endotoxin
levels induced by P. gingivalis administration. Contrary to the systemic effects, propolis had no beneficial effect on
alveolar bone loss.
Conclusion: These results suggest that administration of propolis may be effective in suppressing periodontopathic
bacteria-induced metabolic changes that increase the risk of various systemic diseases.
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Background
Periodontal diseases are mainly chronic infectious dis-
eases resulting from responses to a complex dental
plaque microbiome containing various periodonto-
pathic bacteria species. Epidemiological studies sug-
gest that periodontitis is a risk factor for various
systemic diseases, such as type 2 diabetes [1, 2], ath-
erosclerotic vascular diseases [3, 4], and non-alcoholic
fatty liver disease [5]. Among the various periodonto-
pathic bacteria, considerable research has been fo-
cused on the role of Porphyromonas gingivalis as a
possible mechanism linking periodontal and other hu-
man diseases, due to its unique pathogenicity [6] and
its association with various diseases. Although the
possible significance of common susceptibility cannot
be discounted, there are several hypothetical causal
mechanisms linking periodontal disease and systemic
diseases. First, bacteria from dental plaque invade gin-
gival tissue through ulcerated sulcular epithelial lin-
ings of periodontal pockets and then disseminate into
systemic circulation. Second, various proinflammatory
cytokines produced in inflamed periodontal tissue,
which can also enter systemic circulation, are deliv-
ered to various tissues and organs and thereby induce
an inflammatory response [7].
Interestingly, links between the diseases related to
periodontitis and dysbiosis of the gut microbiota are be-
coming more evident [8, 9]. Recently, we revealed that
oral administration of P. gingivalis altered gut micro-
biota and elicited endotoxemia, thereby inducing sys-
temic inflammation and insulin resistance [10, 11].
Propolis is a plant product collected by honeybees as a
resinous mixture from various plants that is mixed with
beeswax and other bee secretions. Although the chem-
ical composition of propolis depends on its location of
origin, it basically contains beneficial substances, such as
phenolic acids, flavonoids, and vitamins [12, 13]. How-
ever, the details of the main ingredients have not yet
been disclosed.
Propolis has been used as a folk medicine since an-
cient times due to its anti-inflammatory [14, 15], anti-
microbial [16, 17], anti-oxidant [12], and anti-tumour
properties [18, 19]. In addition, previous studies have
shown the beneficial effect of propolis on diabetes melli-
tus. Fuliang et al. revealed that administering propolis
improved blood glucose levels and modulates glucose
and blood lipid metabolism in experimental rat models
of diabetes [20]. Kitamura et al. demonstrated that the
propolis extract restored glucose intolerance and insulin
resistance, as well as blood glucose and plasma choles-
terol levels using ob/ob mice [21]. Furthermore, because
of its effectiveness on enterobacteria [22], propolis is
expected to replace probiotics as a novel regulator of gut
microbiota.
In the present study, we evaluated whether systemic
inflammation and insulin resistance induced by period-
ontopathic bacteria through intestinal reactions could be
suppressed by administering propolis.
Methods
Mice
Eight-week-old male C57BL/6 mice were obtained from
Japan SLC, Inc. (Shizuoka, Japan). The mice were accli-
matized under specific pathogen-free conditions and fed
regular chow and sterile water until the commencement
of infection at nine weeks of age.
Bacterial cultures
P. gingivalis (strain W83) was cultured in modified Gifu
anaerobic medium (GAM) broth (Nissui, Tokyo, Japan)
in an anaerobic jar (Becton Dickinson Microbiology Sys-
tem, Cockeysville, MD, USA) in the presence of an
AnaeroPack™ (Mitsubishi Gas Chemical Co. Inc.,
Tokyo, Japan) for 48 h at 37 °C. Bacterial suspensions
were prepared in phosphate-buffered saline (PBS)
without Mg2+/Ca2+ using established growth curves
and spectrophotometric analysis. The number of
colony-forming units (CFUs) was standardized by
measuring optical density at 600 nm.
Oral administration
The murine experimental periodontitis model was devel-
oped according to Baker et al. with slight modifications
[23]. In the present study, mice did not receive antibiotic
pretreatment before P. gingivalis administration since
systemic antimicrobial treatment affects the gut micro-
biota composition and alters metabolism [24]. In
addition, we have observed P. gingivalis-induced alveolar
bone resorption without antibiotic pretreatment [25]. A
total of 109 CFUs of live P. gingivalis suspended in
100 μL PBS with 2 % carboxymethyl cellulose (Sigma-
Aldrich, St. Louis, MO, USA) was given to each mouse
via a feeding needle three times a week for 5 weeks. The
number of administered bacteria was determined based
on the number of P. gingivalis contained in saliva of pa-
tients with severe periodontitis [26] and adjusted for
body weight. The control group was sham-administered
100 μL PBS with 2 % carboxymethyl cellulose without P.
gingivalis. In the propolis group, powdered ethanol ex-
tracts of propolis mixed with 2 % carboxymethyl cellu-
lose (200 mg/kg weight) were administered every day
during the experimental period in addition to P. gingiva-
lis administration three times a week for 5 weeks. The
propolis ethanol extract, including 55 % propolis extract
as solid content, standardized to contain minimum
8.0 % artepillin C, was obtained from Yamada Bee Com-
pany, Inc. (Okayama, Japan).
Nakajima et al. BMC Complementary and Alternative Medicine  (2016) 16:329 Page 2 of 9
During the experimental period, all mice were allowed
to eat and drink ad libitum. One day after the final treat-
ment, mice were euthanized with CO2 and their tissues
were collected.
Analysis of gene expression in the liver and adipose
tissues
Total RNA from the liver and adipose tissues were
extracted using TRI Reagent® (Molecular Research Cen-
ter, Inc., Cincinnati, OH, USA). cDNA was synthesized
with Transcriptor Universal cDNA Master (Roche Mo-
lecular Systems, Inc., Branchburg, NJ, USA). Primers
and probes specific for real-time PCR were purchased
from Life Technologies Corporation. Reactions were car-
ried out in a final volume of 25 μL in a LightCycler® 96
System (Roche) using TaqMan Gene Expression Assays
(Life Technologies Corporation) containing 900 nM each
of the forward and reverse primers and a 250 nM probe.
The reactions consisted of a 10-min incubation at 95 °C,
followed by 45 cycles of a 2-step amplification pro-
cedure, consisting of annealing/extension at 60 °C for
1 min and denaturation for 15 s at 95 °C. LightCy-
cler® 96 software (Roche) was used to analyze the
standards and carry out the quantification. The rela-
tive quantity of each mRNA was normalized to the
relative quantity of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) mRNA.
Quantification of alveolar bone loss
The amount of bone loss was assessed from images
obtained using a stereomicroscope fitted with a video
image marker measurement system (DP2-BSW;
Olympus, Tokyo, Japan). We determined the area sur-
rounded by the margin of the submaxillary alveolar
bone crest and the cement-enamel junction on the lin-
gual side of the first molar. We measured alveolar
bone loss in the mice in a blind manner.
Endotoxin assay
Endotoxin levels were determined in sera collected at
the end of the experimental period using a Limulus
amebocyte lysate test (QCL-1000TM, BioWhittaker,
Walkersville, MD, USA) according to the manufacturer’s
instructions. Serum samples were diluted 1-to-4 for the
assay. Optical densities were measured using an ELISA
plate reader (Model 680, Bio-Rad Laboratories, Hercules,
CA, USA) at 405 nm.
Histological analysis of the liver tissue
The liver tissues of three mice from each group were
fixed in 10 % formalin. Briefly, samples were embedded
in paraffin, sectioned, and stained with hematoxylin
and eosin.
Statistical analysis
Prior to beginning the present study, the sample size cal-
culation was performed based on the data from our pre-
vious study. With an alpha error of 0.05 and a statistical
power of 0.8, the sample size was calculated to require
more than seven animals in each group. This was veri-
fied by post-hoc analyses. The data were tested for nor-
mality using the Kolmogorov-Smirnov test. Because
some, but not all, data sets showed a parametric distri-
bution even in a particular gene expression among dif-
ferent treatment groups, all data were assessed by the
Kruskal-Wallis test with a post-hoc Dunn’s multiple
comparison test using GraphPad Prism® (GraphPad Soft-
ware, Inc., La Jolla, CA). A probability value of p < 0.05
was considered statistically significant.
Results
Effect of P. gingivalis administration and/or propolis on
the body weight
After treatment with P. gingivalis and propolis, there
were no differences among the sham-administered,
P. gingivalis-administered, or P. gingivalis and propolis-
administered groups in body weight (Fig. 1) or food
intake.
Fig. 1 Effect of oral administration of P. gingivalis or P. gingivalis and
propolis on body weight. Body weight changes during experimental
period in Sham-administered mice (N = 7), P. gingivalis-administered
mice (N = 7), and P. gingivalis and propolis-administered mice (N = 8).
All data are mean ± SD. (*p < 0.05, Kruskal-Wallis test with post-hoc
Dunn’s multiple comparison test)
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Effect of propolis on the altered gene expression in the
liver by P. gingivalis administration
Oral administration of P. gingivalis significantly in-
creased gene expression of Plin2 and Acox, both of
which are associated with lipid metabolism in the
liver, while these gene expressions were markedly re-
duced in the propolis-administered mice (Fig. 2a).
Furthermore, administration of propolis suppressed
G6pc expression, which positively regulates gluconeo-
genesis, compared to mice administered P. gingivalis
alone. Conversely, there was no significant change in
the expression of the insulin signaling gene Irs1
among the three groups (Fig. 2b). Although gene ex-
pression of the proinflammatory cytokines IL-6 and
TNF-α tended to be elevated from the administered
P. gingivalis, administration of propolis had no effect
on the expression of these genes (Fig. 2c).
Administering propolis led to decreased Plin2 and
Acox expression, which were associated with the mitiga-
tion of hepatic steatosis induced by P. gingivalis admin-
istration (Fig. 3).
Effect of propolis on the altered gene expression in the
adipose tissue by P. gingivalis administration
Il6, Tnf, C1qtnf9, and Adipoq are known as adipocyto-
kines that are expressed in adipocytes to modulate glu-
cose and lipid metabolism. The gene expression of the
proinflammatory cytokines IL-6 and TNF-α, which sup-
press insulin signals, tended to be higher in the P. gingi-
valis-administered mice. Conversely, C1qtnf9, a gene
that improves insulin sensitivity, was more frequently
downregulated in the P. gingivalis-administered mice.
Administration of propolis ameliorated these changes to
gene expression induced by P. gingivalis administration
Fig. 2 Effect of oral administration of P. gingivalis or propolis on gene expression in the liver. Expression of genes related to lipid metabolism a,
glucose metabolism b, and inflammation c. Sham-administered mice (N = 7), P. gingivalis-administered mice (N = 7), Propolis-administered mice
(N = 8). The relative mRNA expressions of the genes of interest were normalized to the relative quantity of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) mRNA. All data are means ± SD. (*p < 0.05, Kruskal-Wallis test with post-hoc Dunn’s multiple comparison test)
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(Fig. 4a). Furthermore, the genes that improve insulin
sensitivity, Irs1 and Sirt1, were downregulated in P. gin-
givalis-administered mice. However, propolis administra-
tion reversed the effect of P. gingivalis administration on
the expression of these genes. In addition, administra-
tion of propolis suppressed the P. gingivalis-induced in-
creased expression of Angptl4, a gene that is supposed
to increase insulin resistance (Fig. 4b).
Effect of propolis on the serum endotoxin levels in P.
gingivalis-administered mice
Oral administration of P. gingivalis increased serum
endotoxin levels, but was not statistically significant.
Administration of propolis not only repressed this in-
crease, but also further lowered serum endotoxin levels
below those of untreated mice (Fig. 5).
Effect of propolis on the alveolar bone resorption in P.
gingivalis-administered mice
As with the previous studies, oral administration of
P. gingivalis induced significant alveolar bone resorp-
tion. In spite of the beneficial systemic effect of
administering propolis, no effect was observed on
the P. gingivalis-induced alveolar bone resorption
(Fig. 6).
Fig. 3 Histological analysis of the liver tissue. Sections of liver tissue in a Sham-administered mice, b P. gingivalis- administered mice, and c P. gin-
givalis and propolis-administered mice were H-E stained. Representative results are shown (N = 3 in each group)
Fig. 4 Effect of oral administration of P. gingivalis or propolis on gene expression in the epididymal adipose tissue. a Relative gene expression
of adipocytokine. b Relative expression of genes related to glucose metabolism. Sham-administered mice (N = 7), P. gingivalis-administered mice
(N = 7), P. gingivalis and propolis-administered mice (N = 8). The relative mRNA expressions of the genes of interest were normalized to the
relative quantity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. All data are means ± SD. (*p < 0.05, Kruskal-Wallis test with
post-hoc Dunn’s multiple comparison test)
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Discussion
Periodontal disease is a chronic inflammatory disease
likely resulting from dysbiosis of the oral microbiota.
Epidemiological studies indicate its association with an
increased risk of various diseases, such as diabetes [1, 2],
atherosclerotic vascular diseases [3, 4], and rheumatoid
arthritis [5]. The underlying mechanisms linking peri-
odontal disease and these diseases have been considered
to be endotoxemia and proinflammatory cytokines de-
rived from gingival lesions [7]. We have shown that re-
peated oral inoculation of P. gingivalis induced elevation
of serum inflammatory markers (serum amyloid A and
IL-6) in mice [27]. However, in this mouse model, ad-
ministered P. gingivalis was not detected in the blood or
insulin target tissues and there was little inflammation in
the gingival tissues, suggesting that conventional mecha-
nisms for the relationship between periodontitis and sys-
temic diseases may not be applicable, at least in this
mouse model. Recently, we have also demonstrated
altered gut bacterial composition by repeated oral ad-
ministration of P. gingivalis as a novel underlying mech-
anism [10, 11]. Since the gut microbial changes are
associated with decreased gut barrier function, as evi-
denced by reduced expression of the tight junction pro-
tein gene (Tjp1) and elevated endotoxin levels in the
systemic circulation in our previous studies [10, 11], in-
flammation of adipose and liver tissue seen in the
present study was expected to be from bacteria influx
and/or bacterial products into these tissues.
In the present study, we have demonstrated that oral
administration of P. gingivalis altered gene expression
associated with tissue-specific pathological changes relat-
ing to metabolic syndromes. In the liver, the expression
of Plin2 and Acox1 was significantly upregulated. Plin2
is reported to be strongly associated with lipid droplet
formation in the liver [28] and Acox1 is involved in fatty
acid oxidation [29]. Both genes play important roles
in non-alcoholic fatty liver diseases. P. gingivalis ad-
ministration also seemed to affect glucose metabolism
by increasing the expression of G6pc. G6pc positively
regulates gluconeogenesis and can increase blood glu-
cose levels [30].
Adipose tissue plays an important role in mediating
insulin sensitivity through various molecules, including
adipocytokines. C1qtnf9 encoding C1q/TNF-related pro-
tein (CTRP)9 is a novel and highly conserved paralog of
adiponectin and has salutary effects on glucose metabol-
ism and vascular function [31, 32]. Irs1 [33] and Sirt1
contribute to improving insulin sensitivity. SIRT1 not
only stimulates a glucose-dependent insulin secretion
from pancreatic beta cells, but also directly stimulates
insulin signaling pathways in insulin-sensitive organs
[34]. Tnf and Il6 are further adipocytokines with strong,
natural proinflammatory traits that negatively impact in-
sulin signaling. Angptl4 can also be involved in insulin
resistance [35]. Taken together, oral administration of P.
gingivalis has harmful effects on insulin sensitivity.
Administration of propolis during the experimental
period seemed to show no serious adverse effects, as in-
dicated by no change in body weight among the groups.
In support of previous studies [21, 36], administering
propolis alleviated the detrimental effects on glucose
and lipid metabolism induced by oral administration of
P. gingivalis. Although we have not analyzed the detailed
mechanisms by which propolis suppress these harmful
effects, it is possible that administration of propolis
could affect gut barrier function, either by alteration of
gut microbiota composition or direct elevation of gut
barrier function. In support of this idea, our previous
studies clearly demonstrate that oral administration of P.
gingivalis changes gut microbiota composition, inducing
sustained endotoxemia and systemic inflammation
[10, 11]. Another previous work shows high-fat diet-
induced obesity influences gut microbiota and induces
metabolic endotoxemia [37]. This endotoxemia is con-
sidered to be a result of reduced gut barrier function.
Fig. 5 Effect of oral administration of P. gingivalis or propolis on
endotoxemia. Serum endotoxin (LPS) concentration (EU/mL) were
evaluated in Sham-administered mice (N = 7), P. gingivalis-adminis-
tered mice (N = 7), and P. gingivalis and propolis-administered mice
(N = 8). All data are means ± SD. (*p < 0.05, Kruskal-Wallis test with
post-hoc Dunn’s multiple comparison test)
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In the present study, we also observed that administering
P. gingivalis tended to increase serum endotoxin levels,
while administering propolis completely abrogated the ef-
fect of P. gingivalis. Although administering propolis had
no effect on alveolar bone resorption induced by P. gingi-
valis indicating no local effects on periodontal tissue, low
levels of endotoxin activity in the propolis-administered
mice could be mediated by anti-microbial effect on P. gin-
givalis. In this regard, several studies have demonstrated a
significant antimicrobial effect of propolis on periodonto-
pathic bacteria such as P. gingivalis [38–41] and an inhibi-
tory effect on alveolar bone resorption in ligature-induced
periodontitis in rats [42, 43]. However, our study demon-
strated no suppressive effect of propolis on alveolar bone
resorption. The difference between our study and the
study by Toker et al. [43] could be due at least in
part to the different methods for inducing experi-
mental periodontitis. Alternatively, propolis adminis-
tration may have induced changes in gut microbiota
composition or strengthened the gut barrier func-
tion. One previous study showed that propolis up-
regulated tight junction proteins in Caco-3 cells and
that in vivo administration of propolis increased co-
lonic epithelial ZO-1 expression [44]. Furthermore, it
has been demonstrated that a gut metabolite of lino-
leic acid ameliorates inflammation-induced intestinal
epithelial barrier impairments, suggesting that gut
microbiota composition is crucial for the mainten-
ance of gut barrier function [45]. Thus, it is reason-
able to consider the beneficial effects of propolis on
gut microbiota.
Conclusion
Although further studies are needed to clarify the
underlying mechanism by which propolis suppresses
P. gingivalis-induced metabolic disturbance, our re-
sults suggest that administration of propolis may be
effective in suppressing periodontopathic bacteria-
induced metabolic changes that increase the risk of
various systemic diseases.
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